Vascular Trauma And Dialysis Pipeline Will Transform Long Term Revenue Potential

Catalysts

About Humacyte

Humacyte develops off the shelf bioengineered human vessels for vascular trauma, dialysis access and other cardiovascular applications.

What are the underlying business or industry changes driving this perspective?

• Growing adoption of Symvess in civilian trauma centers, supported by 92 hospitals already eligible to purchase and reports that most early customers are reordering, directly supports potential revenue growth as usage patterns deepen.
• Access to U.S. military and Veterans Affairs facilities through ECAT listing and the positive Ukraine humanitarian data in real world combat injuries position Symvess to benefit from long term demand for vascular solutions in defense and veteran care, which could broaden the revenue base.
• Positive Phase III results for the ATEV in dialysis access, targeting women and high risk men who represent more than half of the dialysis population, align with a large, chronically treated patient group that could influence longer term revenue and earnings if an added indication is approved.
• Planned first in human studies for the coronary tissue engineered vessel in CABG, where few new conduits have entered U.S. practice in decades, offer a potential entry into a large cardiac surgery market that could add new revenue streams over time.
• Expansion of the patent estate covering multiple tubular organs, including esophagus, trachea and urinary conduits with protection into 2041, helps support pricing power and potential future product extensions, which can be important for margin stability and long term earnings potential.

Assumptions

This narrative explores a more optimistic perspective on Humacyte compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Humacyte's revenue will grow by 649.8% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -2353.2% today to 61.8% in 3 years time.
• The bullish analysts expect earnings to reach $408.9 million (and earnings per share of $2.06) by about January 2029, up from $-37.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $16.7 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 15.9x on those 2029 earnings, up from -6.3x today. This future PE is lower than the current PE for the US Biotechs industry at 22.0x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.44%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Humacyte is still in the early stages of commercialization, with third quarter 2025 revenue of US$0.8 million and US$1.6 million for the first nine months of 2025, while net cash used in operating activities was US$78.9 million over that same nine month period. If revenue does not scale meaningfully relative to cash burn, future dilution or funding pressure could weigh on earnings and shareholder returns.
• Symvess uptake currently depends on hospital Value Analysis Committee approvals, price sensitive purchasing departments and individual surgeon champions. Humacyte has already reduced price to help move VAC processes along. Slower than hoped adoption, pushback on pricing or limited reorder volumes could hold back product sales growth and keep gross margin and operating margin under pressure.
• The dialysis access opportunity relies on positive interim results from the V012 Phase III trial and on a supplemental BLA filing planned for the second half of 2026. Any delay, inconclusive data or regulatory hurdle for ATEV in dialysis could postpone or shrink a key long term revenue stream that bullish expectations currently assume will support higher earnings.
• The broader pipeline beyond trauma and dialysis, including coronary artery bypass grafting and tubular organ programs such as esophagus, trachea and urinary conduits, is at preclinical or very early clinical stages and not currently a focus of active development. If these programs remain deprioritized because of cash constraints or technical challenges, the long dated product portfolio that some investors may expect to diversify revenue and improve margins might not materialize.
• Humacyte finished September 30, 2025 with US$19.8 million in cash, cash equivalents and restricted cash and then raised an additional US$56.5 million, which management believes provides runway exceeding 12 months. If operating cash use remains high or increases with inventory build, commercial expansion and new trials, the company may need further capital sooner than investors expect, which could dilute existing shareholders and weigh on per share earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Humacyte is $22.83, which represents up to two standard deviations above the consensus price target of $7.86. This valuation is based on what can be assumed as the expectations of Humacyte's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $3.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $662.1 million, earnings will come to $408.9 million, and it would be trading on a PE ratio of 15.9x, assuming you use a discount rate of 7.4%.
  
• Given the current share price of $1.2, the analyst price target of $22.83 is 94.7% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.